Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 463 clinical trials
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma

This study will test the safety of ipilimumab to see what effects, if any, the drug has when used as maintenance therapy for people with relapsed/refractory multiple myeloma who have received

  • 0 views
  • 04 Feb, 2021
  • 7 locations
Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

To characterize safety associated with the use of Kyprolis under the locally approved label.

  • 0 views
  • 19 Jun, 2021
  • 24 locations
CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma

This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma

  • 0 views
  • 27 Jan, 2021
  • 1 location
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

populations of CD8+ T cells targeting multiple Myeloma associated antigen peptides in patients with relapsed refractory multiple myeloma (MM). The study will enroll patients with MM who have relapsed

  • 0 views
  • 27 Jan, 2021
  • 4 locations
  • 20 views
  • 03 Feb, 2021
  • 45 locations
Daratumumab Pomalidomide and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

This phase II trial studies how well daratumumab, pomalidomide, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed). Immunotherapy with daratumumab

proteasome inhibitor
electrophoresis
vasectomy
dexamethasone
bortezomib
  • 0 views
  • 16 Apr, 2021
  • 10 locations
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.

  • 0 views
  • 08 Mar, 2021
  • 1 location
VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

multiple myeloma with detectable disease activity following tandem high-dose chemotherapy and autologous SCT. The time from SCT to the initiation of VELCADE treatment will be 3 to 6 months.

remission
cell transplantation
bortezomib
melphalan
velcade
  • 16 views
  • 07 Nov, 2020
  • 7 locations
Myeloma-Developing Regimens Using Genomics (MyDRUG)

. The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell

  • 18 views
  • 13 Mar, 2021
  • 14 locations
Autologous Stem Cell Transplant (ASCT) With Intravenous Busulfan and Melphalan as Conditioning Regimen

Analyze the results of ASCT using intravenous Busulfan and Melphalan as conditioning regimen for patients with Multiple Myeloma.

transplant conditioning
line of therapy
lenalidomide
bortezomib
melphalan
  • 14 views
  • 07 Nov, 2020
  • 5 locations